Search

Background: Immunization strategies that elicit antibodies capable of neutralizing diverse strains of the virus will likely be an important part of a successful vaccine against HIV. The envelope trimer is the only neutralizing target on the virus, and strategies to promote durable, high avidity antibody responses against the native intact trimer structure are lacking. We recently developed chemically-crosslinked lipid nanocapsules as carriers of molecular adjuvants and encapsulated or surface-displayed antigens, which promote follicular helper T-cell responses and elicited high-avidity, durable antibody responses to a candidate malaria antigen (Moon et al. Nat. Mater. 10 243 (2011); Moon et al. PNAS 109 1080 (2012)). Methods: To apply this system to the delivery of HIV antigens, we developed a strategy to anchor recombinant envelope trimers to the surfaces of these particles under conditions preserving the antigenic integrity of the trimers, allowing multivalent display of these immunogens for immunization. To anchor trimers in their native orientation, gp140 trimers with terminal his-tags were anchored to the surface of lipid nanocapsules via Ni-NTA-functionalized lipids. Results: Owing to their significant size (409 kDa) and heavy glycosylation, we found that liquid-ordered and/or gel-phase lipid compositions were required to stably anchor trimers to particle membranes. Trimer-loaded nanocapsules carrying monophosphoryl lipid A elicited durable antibody responses with titers comparable to a Complete Freund’s Adjuvant (CFA)-like emulsion in mice, without the toxic inflammation associated with the latter adjuvant. Further, nanocapsules elicited strong helper T-cell responses associated with a steadily increasing avidity of trimer-binding antibody over 90 days, which was not replicated by other adjuvants. Conclusion: These results suggest that nanoparticles displaying HIV trimers in an oriented, multivalent presentation can promote key aspects of the humoral response, National Institutes of Health (U.S.) (AI095109), Massachusetts Institute of Technology. Ragon Institute of MGH, MIT, and Harvard

HLA-A2 is present at high frequency in most populations, as identified by serological and biochemical means. The value of these methods is limited by their failure to discriminate between the products of the 14 known allelic HLA-A*02 variants. The great majority of genetic polymorphism which defines the allelic variants is found in exons 2 and 3 of the A*02 genes. These exons encode the α-1 and α-2 domains of the HLA Class I molecules, and variation within the genes may influence the peptide binding specificity of the gene products of each allele. Failure to accurately assign the allelic types has implications in transplantation, in interpretation of cellular assays and in the understanding of HLA disease associations. We have developed a method for determining the 14 Known alleles of HLA-A*02 by use of ARMS–PCR to determine the degree of variation of HLA-A*02 alleles in 3 different population groups. Considerable variation was found in the relative frequencies of particular A*02 alleles between Caucasian, oriental and black individuals. Our results indicate the importance of ethnic origin in terms of the expected HLA-A*02 allelic profile, and emphasize the functional significance of allele supecific subtyping of HLA-A*02.